SAN FRANCISCO, Sept. 13, 2022 /PRNewswire/ — ValGenesis, Inc. and Xevalics Consulting have partnered to ship best-in-class digital validation options for the life sciences business throughout the U.S.
ValGenesis is the market chief in enterprise Validation Lifecycle Administration Methods (VLMS), serving to the world’s main life sciences firms implement compliance and allow standardization with 100% digital, risk-based validation software program.
Xevalics is a consulting firm specializing in laptop software program assurance (CSA), laptop system validation (CSV), and threat administration. Xevalics has years of expertise in strategically remodeling complicated issues into manageable and tractable initiatives.
On this partnership, Xevalics will implement and handle next-generation digital validation instruments developed by ValGenesis, enabling shoppers to additional strengthen CSA and threat and compliance throughout the GMP lifecycle. With ValGenesis expertise, Xevalics will serve a wider community of life sciences firms throughout the U.S. and the globe. This mixed experience permits pharma firms to carry merchandise to market quicker in accordance with the rules of Trade 4.0 and MISE.
“Pharmaceutical manufacturing is quickly innovating and corporations are discovering new methods to create worth, however GMP compliance stays the foremost concern,” says Bo Olsen, ValGenesis’ SVP of Companions. “To satisfy stringent regulatory necessities and to get their merchandise to market extra safely and rapidly, it’s essential that firms embrace digitalization. Our partnership with Xevalics leverages each our strengths to supply a real digital validation technique that creates compelling worth for purchasers,” he said.
“Many firms within the life sciences business are experiencing uneasy moments figuring out when and how you can begin totally incorporating CSA practices,” mentioned Ricardo Torres-Rivera, CEO/President of Xevalics. “Along with ValGenesis, our aim is to empower shoppers to evolve their enterprise and harness the facility of the FDA’s CSA initiative by embracing paperless, agile, and risk-based digital validation processes. With this partnership, we’re propelling our capabilities to carry a market chief VLMS expertise, superior venture administration, validation, high quality, and regulatory information to attain agile and profitable implementations for quicker and larger advantages to our shoppers,” he said.
About Xevalics Consulting
Xevalics is a consulting firm specializing in laptop software program assurance (CSA), laptop system validation (CSV), threat administration, information integrity, high quality, compliance and regulatory companies, digital transformation and knowledge expertise (IT), and cloud computing and cybersecurity. Xevalics is a ahead transferring firm offering strategic value-added options for essentially the most complicated challenges by enriching the connection between individuals and expertise. For extra info, go to https://xevalics.com/.
ValGenesis, Inc. is the creator of an revolutionary software program platform that serves as a basis for managing compliance-based validation actions in life science firms. ValGenesis, Inc. is the supplier of the primary enterprise software that manages the company validation lifecycle course of. This answer is totally compliant with U.S. FDA 21 CFR Half 11 and Annex 11 necessities. As the primary totally paperless answer for digital administration of validation execution and approval, ValGenesis was chosen by an business peer evaluate committee to obtain the Parenteral Drug Affiliation (PDA) New Modern Know-how Award in 2005. For extra info, go to https://www.valgenesis.com/.
Ricardo Torres-Rivera, Xevalics Consulting, +1 787-603-2946,
Althea D’Sylva, ValGenesis Communications, +1 510-445-0505 Ex. 1026,
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/valgenesis-and-xevalics-consulting-partner-to-deliver-best-in-class-computer-software-assurance-and-risk-management-solutions-for-life-sciences-companies-across-the-us-301622056.html
SOURCE ValGenesis Inc.